Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Hepatology
•
Alcohol-associated Liver Disease
How has the move away from a strict 6 month period of sobriety impacted your patient selection criteria for transplant of patients with alcohol associated liver disease?
Related Questions
With the growth of non-alcoholic beverages (e.g., NA beer, liquor, etc), how do you approach a patient's consumption of these products in the setting of alcohol related liver disease?
What factors into your choice to use craving-related medications (e.g., baclofen, naltrexone, acamprosate, etc.) in the management of alcohol use disorder?
How do you approach a conversation with a patient with a markedly positive PETH (>200 ug/L) who is insistent that they do not consume any alcohol?
How do you incorporate addiction medicine and counseling into your treatment plan for patients with alcohol associated liver disease?
How has the GALAD score affected your practice for HCC screening?
When would you choose to measure a patient's spleen stiffness?
In what scenarios do you defer treatment of a patient's hepatitis C if they are undergoing liver transplant evaluation?
How do you approach restarting immunotherapy in a patient with metastatic melanoma who previously developed immune-mediated hepatitis (Grade 3), with liver enzymes now back to baseline levels?
What are your biggest takeaways from the MASH-TAG 2025 conference?
How do you utilize liver assisive devices in the management algorithm of patients with acute liver failure?
